Novo Nordisk A/S (NOVO-B.CO)
| Previous Close | 884.80 |
| Open | 879.70 |
| Bid | 902.60 x 0 |
| Ask | 904.80 x 0 |
| Day's Range | 869.40 - 916.90 |
| 52 Week Range | 504.40 - 932.00 |
| Volume | |
| Avg. Volume | 2,725,879 |
| Market Cap | 4.027T |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 48.58 |
| EPS (TTM) | 18.58 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | 12.80 (1.45%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | 914.72 |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
- Yahoo Finance Video
Why these analysts are bullish on healthcare stocks
The healthcare sector has underperformed throughout 2024, but as the first quarter earnings season unfolds, Jefferies Healthcare Services Equity Research Analyst Brian Tanquilut and Grey Ghost Advisors Private Equity Investor Meghan Fitzgerald join Market Domination to discuss how investors should position themselves in this market. Fitzgerald remains bullish on the healthcare sector, believing it still has "a lot of long and important tailwinds." She cites the sector's historical outperformance during market downturns and election years as reasons for her optimism. Fitzgerald anticipates strong earnings from companies with GLP-1 drug portfolios this week, describing it as an "easy beat." Tanquilut notes a "rise in broader healthcare utilization trends," which is now reflected in healthcare insurers' earnings. While there has been weakness in this area, he highlights the "strength in volume" from healthcare providers. However, Tanquilut acknowledges that with consumer spending slowing, consumer-focused healthcare segments, such as drugstores, have experienced pressure. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's note: This article was written by Angel Smith
Investor's Business DailyIBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
